🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Watch our presentation from the #JPM2025 Healthcare Conference, discussing how our therapies are helping redefine possibilities for patients, including the FDA accelerated approval for the treatment of HER2-positive #BiliaryTractCaner (BTC): bit.ly/42jIjCf

We’re committed to advancing clinical trial research to help address the unmet needs of patients living with difficult-to-treat cancers. Our current trial explores the role HER2 can play in uncontrolled cell growth. Learn more: bit.ly/3X2SXKd

Jazz announces fourth quarter and full year 2024 financial results $JAZZ: bit.ly/41xlgTO

For over 20 years, we have been committed to patient-centric practices across our #narcolepsy and idiopathic #hypersomnia research. Read more about how we strive to address the priorities of people with these conditions through our research: bit.ly/4imTkaH

We’re attending the @AANMember Annual Meeting, where we're sharing seven abstracts, showcasing research findings from our neuroscience portfolio. Learn more about our data being shared at #AANAM here: bit.ly/4hnCCr1

We’re pleased to announce we have completed the acquisition of Chimerix, strengthening our presence in rare #oncology and reinforcing our commitment to people living with rare diseases with significant unmet need bit.ly/3Er2RiR

At #ASCO25, we will present 7 #oncology abstracts alongside partners, including clinical trial data for extensive-stage small cell lung cancer (ES-SCLC), metastatic gastroesophageal adenocarcinoma (mGEA) and diffuse glioma. Read more: bit.ly/4jqXYWe

Jazz announces 2025 first quarter financial results $JAZZ: bit.ly/434f458

At #ASCO25, we look forward to presenting new data in small cell lung cancer (SCLC), one of the most aggressive forms of cancer. Read about the evolving science behind SCLC therapies and how the scientific community is uncovering new hope for patients: bit.ly/4kEJVwy

We’ll be at #ASCO25 to share the latest data from our oncology portfolio. Visit us at booth 33077 to learn how we’re advancing the science behind treatments for difficult-to-treat cancers to help improve patient outcomes or booth 10051 to learn about our clinical trials.

We are looking forward to #SLEEP2025, where we’ll be sharing extensive new research findings from across our sleep medicine portfolio. Learn more about our data: bit.ly/3FylcLj

At #ASCO25, we're presenting Phase 2 trial data evaluating the potential of our investigational treatment for patients with HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). Learn more: bit.ly/43IfdeO

At #ASCO25, we're presenting results from a Phase 3 trial for adult patients with extensive-stage small cell lung cancer (ES-SCLC). Learn more: bit.ly/4kPNiAJ

We’re committed to advancing research that sheds light on the experiences of people living with sleep conditions. Learn more about our patient-centric approach to R&D and our presence at #SLEEP2025 from Sarah McMahon, Sleep Franchise Head: bit.ly/4dOMsSr

Four of our late-breaking abstracts, selected for scientific quality, will comprise all industry-sponsored late-breaking oral presentations featured at #SLEEP2025. Data presented include new Phase 4 results among people living with narcolepsy. See more: bit.ly/3SFWHin

People living with #narcolepsy can have an increased risk of developing cardiovascular comorbidities. Understanding the impact of modifiable risk factors, like sodium intake, can be an important step for those living with this challenging condition.

Our Corporate Sustainability and Social Impact strategy remains fundamental to our purpose, underpinning our corporate strategy and enabling us to deliver life-changing medicines for patients with limited options. Read our 2024 report here: bit.ly/4kabHA9

The European Commission has granted conditional approval of our treatment for adults with advanced HER2+ biliary tract cancer (BTC). Learn more: bit.ly/46oL6Mt

We’re at #ESMOGI25 to present data and connect with the global #GastricCancer community as we share insights and seek solutions for those living with gastrointestinal #cancers.

We’re pleased to announce we have named Renee Gala as Jazz’s President and CEO effective August 11. bit.ly/3IicaTF